2023 World Conference on Lung Cancer (Posters)-EP06.02. Prevalence of PD-L1 Expression in Non-Small Cell Lung Cancer: a Real-World Australian Perspective

EP06.02. Prevalence of PD-L1 Expression in Non-Small Cell Lung Cancer: a Real-World Australian Perspective - PDF(Slides)

Back to course

Pdf Summary

A study was conducted in Australia to assess the prevalence of PD-L1 expression in non-small cell lung cancer (NSCLC) patients. A total of 6690 de-identified PD-L1 immunohistochemistry (IHC) results from NSCLC patients diagnosed between January 2018 and January 2020 were analyzed. The study found that the prevalence of PD-L1 expression in NSCLC patients in the Australian population was comparable to reports from clinical trials and real-world studies. <br /><br />The study also compared the PD-L1 expression based on different factors. It was observed that the PD-L1 IHC scores were higher in females compared to males at 1% cutoff, but gender did not have a significant effect at the 50% cutoff. PD-L1 expression based on histologic type showed no significant difference between squamous cell carcinoma and adenocarcinoma. The study also compared the prevalence of PD-L1 expression based on different specimen types and found that the scores were equal in cytology and biopsies, but higher in cytology compared to surgical resections.<br /><br />Additionally, the study compared the prevalence of PD-L1 expression based on different PD-L1 assay systems. It was observed that the PD-L1 Tumor Proportion Scores (TPS) were marginally higher with the Dako 22C3 assay compared to the PD-L1 SP263 assay. The study also found that metastatic sites showed higher PD-L1 expression compared to primary sites.<br /><br />Overall, the study provides a real-world perspective on the prevalence of PD-L1 expression in NSCLC patients in Australia. The results are consistent with previous studies and clinical trials and suggest that the prevalence of PD-L1 expression in NSCLC patients in Australia is similar to other populations worldwide. This information can be valuable for clinicians in guiding treatment decisions and optimizing patient outcomes. The study was funded by AstraZeneca and conducted in accordance with ethical guidelines.

Asset Subtitle

Sarita Prabhakaran

Meta Tag

Speaker Sarita Prabhakaran

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

Australia

PD-L1 expression

NSCLC patients

immunohistochemistry

clinical trials

gender

histologic type

specimen types

Tumor Proportion Scores

metastatic sites